Back to home
MRNA logo

Is MRNA (Moderna, Inc.) Halal or Haram?

NASDAQ Global SelectHealthcareBiotechnology$18.70B2026-04-29
MRNA is Doubtful3/4 screens passed

Moderna passes the core business activity screen, as biotechnology and vaccine development are inherently permissible. However, the stock is currently classified as Doubtful because its interest income to revenue ratio sits at a high 16.15%, well above the 5% AAOIFI threshold. Fortunately, its debt-to-market cap ratio remains exceptionally low at 10.2%, easily passing the leverage screen.

Price Chart (5D)

$47.64+1.76 (+3.84%)
2026-06-082026-06-01

MRNA — Last 7 Days

DateOpenHighLowCloseVolumeChange
2026-06-0848.2248.9946.8047.604.0M-1.29%
2026-06-0550.7751.5346.3847.446.1M-6.56%
2026-06-0449.4051.9048.9451.596.7M+4.43%
2026-06-0345.3049.5545.3049.066.9M+8.30%
2026-06-0245.3546.1743.9045.645.7M+0.64%
2026-06-0147.0747.0744.2046.066.2M-2.15%
2026-05-2947.2749.2646.8247.196.3M-0.17%

Discussion

Sign in to join the discussion

Loading comments...

Shariah Screening Details for MRNA

Business Activity

Permissible

Moderna's core business of developing and commercializing mRNA therapeutics and vaccines for infectious and rare diseases is considered halal and permissible under Islamic principles.

Debt / Market Cap

10.25%

Debt: $1.92BThreshold: ≤33%

Interest Income

16.15%

Interest: $314.0MThreshold: ≤5%

Cash & Securities

31.02%

Cash: $5.80BThreshold: ≤33%

About Moderna, Inc. (MRNA)

Moderna is a leading biotechnology company globally recognized for pioneering messenger RNA (mRNA) therapeutics and vaccines. Its product pipeline targets infectious diseases, immuno-oncology, and rare diseases, most notably including its widely distributed COVID-19 and respiratory syncytial virus (RSV) vaccines.

For Muslim investors, Moderna currently holds a Doubtful status under AAOIFI standards despite its halal core business. While the company easily passes the debt and cash screening criteria, it fails the interest income screen, meaning investors must carefully weigh this non-compliant revenue stream before adding it to their portfolios.

From an Islamic finance perspective, Moderna boasts a highly conservative balance sheet with a debt-to-market cap ratio of just 10.2%. However, the company generates significant interest from its massive cash reserves, pushing its interest income to revenue ratio to 16.15%, which far exceeds the strict 5% limit allowed for halal investments.

Since the primary issue is interest generated from cash rather than an impermissible core business, some investors may choose to calculate and purify these earnings. Moving forward, halal investors should monitor Moderna's revenue growth and cash management strategies to see if this interest ratio drops back below the compliance threshold.

CEO

Stéphane Bancel

Employees

5,800

IPO Date

2018-12-07

Headquarters

Cambridge, MA, US

MRNA Key Financial Statistics

Revenue

$1.94B

Net Income

$-2.82B

EPS (Diluted)

$-7.26

Stock Price

47.14

Beta

1.34

52-Week Range

22.28-59.55

Total Debt

$1.92B

Total Equity

$8.65B

Current Ratio

3.29

MRNA Financial Health & Profitability

Profit Margins

Gross Margin55.3%
Operating Margin-158.1%
Net Margin-145.2%

Revenue Growth (YoY)

-39.2%

Prior year: $3.20B

Net Cash

$679.0M

Cash: $2.60B — Debt: $1.92B

R&D Spending

$3.13B

% of Revenue

161.1%

Frequently Asked Questions About MRNA

Is MRNA (Moderna, Inc.) stock halal to invest in?
Based on our AAOIFI-standard shariah screening, MRNA is classified as Doubtful. It passed 3 of 4 compliance screens. Some scholars may permit investing with income purification, while others advise avoiding it. We recommend consulting a qualified Islamic scholar before investing in MRNA.
What does Moderna, Inc. do?
Moderna is a leading biotechnology company globally recognized for pioneering messenger RNA (mRNA) therapeutics and vaccines. Its product pipeline targets infectious diseases, immuno-oncology, and rare diseases, most notably including its widely distributed COVID-19 and respiratory syncytial virus (RSV) vaccines. For Muslim investors, Moderna currently holds a Doubtful status under AAOIFI standards despite its halal core business. While the company easily passes the debt and cash screening criteria, it fails the interest income screen, meaning investors must carefully weigh this non-compliant revenue stream before adding it to their portfolios. From an Islamic finance perspective, Moderna boasts a highly conservative balance sheet with a debt-to-market cap ratio of just 10.2%. However, the company generates significant interest from its massive cash reserves, pushing its interest income to revenue ratio to 16.15%, which far exceeds the strict 5% limit allowed for halal investments. Since the primary issue is interest generated from cash rather than an impermissible core business, some investors may choose to calculate and purify these earnings. Moving forward, halal investors should monitor Moderna's revenue growth and cash management strategies to see if this interest ratio drops back below the compliance threshold. Moderna, Inc. operates in the Healthcare sector under the Biotechnology industry and is headquartered in Cambridge, MA, US. The company is led by CEO Stéphane Bancel and employs approximately 5,800 people.
What screening criteria were used for MRNA?
MRNA was screened using AAOIFI-based shariah compliance criteria. Four tests are applied: (1) Business Activity — the company's core business must not derive primary income from haram (prohibited) activities such as alcohol, gambling, tobacco, or interest-based finance. (2) Debt-to-Market-Cap — total debt must not exceed 33% of market capitalization. (3) Interest Income — interest income must not exceed 5% of total revenue. (4) Cash & Securities — cash and interest-bearing securities must not exceed 33% of market cap. MRNA passed 3 of these 4 screens.
When was MRNA last screened?
MRNA was last screened on 2026-04-29. Shariah compliance status can change as companies report new financial data, acquire new businesses, or shift revenue streams. We recommend checking back periodically for the most up-to-date screening results.

Disclaimer

This shariah compliance assessment for MRNA (Moderna, Inc.) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-29.

Other Screened Stocks in Healthcare